Roche Receives EU Approval for New Subcutaneous Formulation of RoACTEMRA Providing more Treatment Flexibility for Patients with Moderate to Severe Rheumatoid Arthritis
Apr 28, 2014
Roche Receives EU Approval for New Subcutaneous Formulation of RoACTEMRA Providing more Treatment Flexibility for Patients with Moderate to Severe Rheumatoid Arthritis
Roche Receives EU Approval for New Subcutaneous Formulation of RoACTEMRA Providing more Treatment Flexibility for Patients with Moderate to Severe Rheumatoid Arthritis
